![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
NM Griffiths, BH Hirst and NL Simmons
Department of Physiological Sciences, Medical School, University of Newcastle upon Tyne, United Kingdom.
The transepithelial transport of three fluoroquinolones, norfloxacin, ciprofloxacin and pefloxacin has been compared by using cultured human intestinal Caco-2 cell-layers. Absorptive (apical-basal) fluxes of ciprofloxacin and norfloxacin are small relative to basal to apical fluxes. Norfloxacin and ciprofloxacin are thus subject to active transepithelial secretion. Active net secretion of norfloxacin displays saturation kinetics with Vmax and Km values of 36.2 +/- 6.9 nmol.cm- 2.hr-1 and 1.42 +/- 0.79 mM. In contrast, transepithelial pefloxacin fluxes are large, show marked saturation while the direction of net flux is variable and small relative to transepithelial fluxes. Norfloxacin, pefloxacin and ciprofloxacin are all subject to accumulative transport across the basal surface of Caco-2 cell layers. A number of 4-quinolones and fluoroquinolones are capable of inhibition of both net secretion of ciprofloxacin and cellular accumulation across the basal-lateral cell surface. Cinoxacin, a 4-quinolone may selectively inhibit exit from the cell across the apical membrane. Cross-competition studies suggest that fluoroquinolones may compete for a common carrier at the basal-lateral membrane. It is likely that the mechanism of transepithelial secretion involves a common accumulative transport at the basal-lateral membrane followed by facilitated exist across the apical membrane. Pefloxacin may interact with a brush-border carrier for which norfloxacin and ciprofloxacin are poor substrates, enhancing the absorptive flux of this fluoroquinolone.
This article has been cited by other articles:
|
|
 |
|
  G. Merino, A. I. Alvarez, M. M. Pulido, A. J. Molina, A. H. Schinkel, and J. G. Prieto BREAST CANCER RESISTANCE PROTEIN (BCRP/ABCG2) TRANSPORTS FLUOROQUINOLONE ANTIBIOTICS AND AFFECTS THEIR ORAL AVAILABILITY, PHARMACOKINETICS, AND MILK SECRETION Drug Metab. Dispos., April 1, 2006; 34(4): 690 - 695. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Miret, L. Abrahamse, and E. M. de Groene Comparison of in Vitro Models for the Prediction of Compound Absorption across the Human Intestinal Mucosa J Biomol Screen, October 1, 2004; 9(7): 598 - 606. [Abstract] [PDF]
|
|
|
|
 |
|
 H. Sasabe, Y. Kato, T. Suzuki, M. Itose, G. Miyamoto, and Y. Sugiyama Differential Involvement of Multidrug Resistance-Associated Protein 1 and P-Glycoprotein in Tissue Distribution and Excretion of Grepafloxacin in Mice J. Pharmacol. Exp. Ther., August 1, 2004; 310(2): 648 - 655. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Yamaguchi, I. Yano, H. Saito, and K.-i. Inui Pharmacokinetic Role of P-Glycoprotein in Oral Bioavailability and Intestinal Secretion of Grepafloxacin in Vivo J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 1063 - 1069. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Naruhashi, I. Tamai, N. Inoue, H. Muraoka, Y. Sai, N. Suzuki, and A. Tsuji Involvement of Multidrug Resistance-Associated Protein 2 in Intestinal Secretion of Grepafloxacin in Rats Antimicrob. Agents Chemother., February 1, 2002; 46(2): 344 - 349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Yamaguchi, I. Yano, Y. Hashimoto, and K.-I. Inui Secretory Mechanisms of Grepafloxacin and Levofloxacin in the Human Intestinal Cell Line Caco-2 J. Pharmacol. Exp. Ther., October 1, 2000; 295(1): 360 - 366. [Abstract] [Full Text]
|
|
|
|
|
|
M. Murata, I. Tamai, H. Kato, O. Nagata, H. Kato, and A. Tsuji Efflux Transport of a New Quinolone Antibacterial Agent, HSR-903, across the Blood-Brain Barrier J. Pharmacol. Exp. Ther., July 1, 1999; 290(1): 51 - 57. [Abstract] [Full Text]
|
|
|
|
|
|
L. Posho, L. Delbos-Bocage, D. Gueylard, R. Farinotti, and C. Carbon Effects of Salmonella typhimurium Infection and Ofloxacin Treatment on Glucose and Glutamine Metabolism in Caco-2/TC-7 Cells Antimicrob. Agents Chemother., November 1, 1998; 42(11): 2950 - 2955. [Abstract] [Full Text]
|
|
|
|
|
|
Y. Matsuo, I. Yano, T. Ito, Y. Hashimoto, and K.-I. Inui Transport of Quinolone Antibacterial Drugs in a Kidney Epithelial Cell Line, LLC-PK1 J. Pharmacol. Exp. Ther., November 1, 1998; 287(2): 672 - 678. [Abstract] [Full Text]
|
|
|
|
|
|
E. Cormet-Boyaka, J.-F. Huneau, A. Mordrelle, P. N. Boyaka, C. Carbon, E. Rubinstein, and D. Tomé Secretion of Sparfloxacin from the Human Intestinal Caco-2 Cell Line Is Altered by P-Glycoprotein Inhibitors Antimicrob. Agents Chemother., October 1, 1998; 42(10): 2607 - 2611. [Abstract] [Full Text]
|
|
|
|
|
|
T. Ito, I. Yano, K. Tanaka, and K.-I. Inui Transport of Quinolone Antibacterial Drugs by Human P-Glycoprotein Expressed in a Kidney Epithelial Cell Line, LLC-PK1 J. Pharmacol. Exp. Ther., August 1, 1997; 282(2): 955 - 960. [Abstract] [Full Text]
|
|
|
|
|
|
H. Sasabe, T. Terasaki, A. Tsuji, and Y. Sugiyama Carrier-Mediated Hepatic Uptake of Quinolone Antibiotics in the Rat J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 162 - 171. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
